NEW YORK, April 29, 2013 /PRNewswire/ -- Anterios, Inc., a privately held aesthetic medicine and medical dermatology biopharmaceutical company, announced today that CEO and Founder, Jon Edelson, MD will be presenting at Needham & Company's 12th Annual Healthcare Conference in New York City on April 30, 2013. Dr. Edelson will be joining a roster of presenters that includes senior management from some of the most well respected public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology, and Diagnostics sectors.
"I'm looking forward to presenting at Needham's Annual Healthcare Conference and sharing with the investment community the latest company news from Anterios," stated Dr. Edelson. "We are at an important phase of our clinical development with ANT-1207, our topical botulinum prescription product. ANT-1207 has true potential for expanding the aesthetic and medical dermatology marketplace."
ANT-1207, Botulinum Toxin Type A, Topical Lotion, is an investigational product being developed for the potential treatment of facial wrinkles, hyperhidrosis (excessive sweating) and other FDA-approved clinical indications for injectable botulinum as well as new potential clinical indications such as acne. The Company believes that this treatment has the potential to greatly expand the market for botulinum as it would overcome the limitations of injection, which include pain, bleeding and bruising as well as the potential for needle misplacement.
ANT-1207 is a lotion that takes five to ten minutes to apply in the physician's office, where it is fully massaged into the skin. Unlike many botulinum-based products, ANT-1207 does not require reconstitution in the physician's office prior to use, making it convenient and time-saving for the physician and the physician's staff. ANT-1207 incorporates a highly purified botulinum developed from Anterios' proprietary cell line of C. Botulinum Type A.
ANT-1207 has been studied for the indications of lateral canthal lines (Crow's Feet wrinkles), hyperhidrosis and acne in multi-center, double-blind, randomized, controlled, dose-escalation studies enrolling approximately 250 subjects. These studies demonstrated that ANT-1207 was well tolerated and demonstrated clinically and statistically significant efficacy versus controls. The Company is currently conducting Phase 2b clinical trials on ANT-1207.
About Anterios, Inc.
Anterios, Inc. ("Anterios") is a privately held clinical stage biopharmaceutical company which is developing next generation botulinum-based prescription products for aesthetic medicine and dermatology. Anterios has developed a proprietary platform technology that enables local, targeted delivery of botulinum toxin and other macromolecules across the skin without needles or other invasive treatments that can be destructive to the skin. In the future, Anterios plans to develop additional dermatology products to topically deliver other active ingredients, as well as products for delivery by other modalities. More information can be found at www.anteriosinc.com.
SOURCE Anterios, Inc.
Help employers find you! Check out all the jobs and post your resume.